India’s pharmaceutical regulatory framework has reached a decisive juncture where quality, accountability, and patient safety must override commercial convenience. Recent developments and industry reactions clearly indicate that the debate is no longer about who manufactures a drug, but about who ultimately bears responsibility for the quality of medicines reaching patients.
The CIPMMA Resolution and Its Implications
At its 15th General Body Meeting, the Chennai-based Consortium of Indian Pharmaceutical Marketers and Manufacturers Associations (CIPMMA) passed a resolution urging the Union Health Ministry to exempt pharmaceutical marketing companies from responsibility for drug quality and regulatory compliance.
CIPMMA’s argument is rooted in the historical context of pharmaceutical marketing in India. Until 2021, marketing companies were largely engaged in merchandising medicines either as agents of licensed manufacturers or by sourcing products from third-party manufacturers. Under the earlier interpretation of the Drugs & Cosmetics framework, legal liability for quality failures rested almost entirely with the manufacturer, not with the marketer whose brand name appeared prominently on the product.
However, this regulatory gap was precisely what prompted reform.
Why the 2021 Amendment Was Necessary
Recognising long-standing loopholes, the Union Health Ministry amended the Drugs & Cosmetics Rules to bring pharmaceutical marketing companies within the regulatory ambit, making them accountable for the quality of drugs they market. This amendment came into force on March 1, 2021.
Crucially, the Ministry did not act in isolation. It had the backing of the Drugs Technical Advisory Board (DTAB)—the country’s highest technical advisory body on drugs. DTAB had recommended that responsibility must extend to entities that market drugs without owning manufacturing facilities but using licensed facilities of other manufacturers.
This reform acknowledged an uncomfortable truth: branding power without accountability is a systemic risk.
The Fallacy of the Marketers’ Argument
CIPMMA contends that marketing companies are not involved in manufacturing processes and therefore should not be held responsible for quality. On the surface, this may sound logical. In practice, however, it is deeply flawed.
India has thousands of pharmaceutical marketing companies, many of them operating powerful brands with deep penetration among doctors and patients. Even leading pharma majors often outsource manufacturing to smaller units under third-party arrangements while selling the products under their own well-known brand names.
For the patient, the brand represents trust. The common man naturally assumes that the reputed company whose name appears on the strip is also responsible for the product’s quality. Yet, when quality failures occur, these very companies disappear from the regulatory picture, leaving small and medium third-party manufacturers to face the full brunt of punitive action.
This asymmetry is neither fair nor sustainable.
- The Legal Grey Zone of Third-Party Manufacturing
- One of the most problematic aspects of India’s pharmaceutical ecosystem is that there is no explicit provision for third-party manufacturing arrangements in the Drugs & Cosmetics Rules, 1945.
- Legally, drugs can be manufactured only through:
- An own manufacturing licence
- A repacking licence
A loan licence (Form 25A or 28A), granted under defined conditions
While the Rules do not explicitly prohibit third-party manufacturing agreements, this silence has been systematically exploited. Major marketers enter into MoUs with smaller manufacturers without assuming any statutory obligations, even though it is their brand equity that drives sales.
As a result:
- Small manufacturers carry disproportionate legal and regulatory risk
- Marketers enjoy commercial upside without accountability
- Quality failures undermine public confidence in the pharmaceutical system
- This regulatory ambiguity called for correction—and the Health Ministry’s amendment addressed precisely this imbalance.
Accountability Is Central to Drug Quality
The 2021 amendment was not an anti-industry move; it was a pro-patient, pro-quality reform. By holding marketers accountable, the government aimed to ensure that:
- Brand owners exercise due diligence in selecting manufacturing partners
- There is shared responsibility for compliance, audits, and quality assurance
- The incentive structure shifts from mere cost optimisation to sustained quality control
- Expecting marketing companies to stand behind the quality of products sold under their own brand names is neither unreasonable nor excessive—it is basic regulatory logic.
- Cooperation, Not Resistance, Is the Way Forward
- Instead of resisting the reform, marketing companies should see this change as an opportunity to:
- Strengthen internal quality governance
- Build transparent, compliant relationships with manufacturers
- Enhance long-term brand credibility with doctors, regulators, and patients
- In a country where medicines are often a matter of life and death, quality cannot be outsourced, diluted, or deflected.
Conclusion: Quality Above All Else
India’s pharmaceutical success story has been built on scale and affordability. The next phase must be built on unambiguous accountability and uncompromising quality.
The Health Ministry’s decision to make marketers responsible for drug quality was a necessary and timely correction. Any attempt to roll it back would reopen old loopholes and weaken patient safety safeguards.
In the final analysis, one principle must guide policy and practice alike:
Those who profit from a brand must also stand fully accountable for its quality.
Only then can quality truly reign supreme.
The article has been crafted by Nikhil Mani Tripathi, Co-founder, Chairman, C.E.O. AMOLYT LIFESCIENCES
